Skip to content

Earnings yield at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
3.6%-1.9pp
Amgen logo
AmgenAMGN
4.1%+0.6pp
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-9.9%-2.8pp
Vor Biopharma logo
Vor BiopharmaVOR
-733.6%-1,389pp
Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE
-4.5%-2.0pp
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
-1.7%-3.6pp

Other financials

Income statement

See full
Revenue$396.0K-81.8%
Operating income-$46.5M-40.3%
Net income-$40.8M-38.4%
EPS (diluted)-$0.85-3.7%

Balance sheet

See full
Cash & equivalents$627.7M+6,105%
Total debt$1.4M-2.3%
Total equity$1.2B+266%
Total assets$1.2B+258%

Cash flow

See full
Operating cash flow-$28.9M-4.4%
CapEx$10.0K-58.3%
Free cash flow-$28.9M-4.4%

Valuation

See full
Market cap$5.01B+823%
Enterprise value$4.38B+721%
P/S1,626.3×+1,068×

Profitability

See full
Operating margin-4,558.4%-9,354pp
Net margin-4,104.8%-7,304pp
FCF margin-3,561.6%-6,956pp

Returns & leverage

See full
Return on equity-28.6%+3.2pp
Debt / equity0.0×
Current ratio29.3×+13.3×

Where this comes from

Calculated from Dianthus Therapeutics’s reported figures.

Based on trailing twelve months.

The official record: Dianthus Therapeutics’s 10-Q, filed November 5, 2025, on SEC EDGAR. View the filing →

Ask your AI about Dianthus Therapeutics's earnings yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Dianthus Therapeutics's earnings yield?
Dianthus Therapeutics (DNTH) reported earnings yield of -8.1% in Q3 2025.
How has Dianthus Therapeutics's earnings yield changed year-over-year?
Dianthus Therapeutics's earnings yield decreased by 12.7% year-over-year, from -7.2% to -8.1%.
What is the long-term trend for Dianthus Therapeutics's earnings yield?
Over 4 years (2020 to 2024), Dianthus Therapeutics's earnings yield has grown at a -9.6% compound annual growth rate (CAGR), from -19.7% to -13.2%.
What does earnings yield mean?
Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.